Everolimus/Strong CYP3A4 Inhibitors; Darunavir Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your liver processes everolimus.
What might happen:
The amount of everolimus in your blood may increase and cause more side effects than normal.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to check the amount of medicine in your blood.Let your doctor know right away if you have a new or worsening cough, shortness of breath, difficulty breathing, wheezing, fever, chills, or do not feel well.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Afinitor (everolimus) US prescribing information. Novartaris Pharmaceuticals Corporation February, 2020.
- 2.Zortress (everolimus) US prescribing information. Novartis Pharmaceuticals Corporation Sept, 2023.
- 3.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-a nd-adolescent-arv/whats-new March 23, 2023.
- 4.Sparkes T, Lemonovich TL. Interactions between anti-infective agents and immunosuppressants-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019 Feb 28; e13510.
- 5.Sporanox (itraconazole) US prescribing information. Janssen Pharmaceutica Products, L.P. February, 2024.
- 6.Billaud EM, Antoine C, Berge M, Abboud I, Lefeuvre S, Benammar M, Glotz D. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. Clin Drug Investig 2009;29(7):481-6.
- 7.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 8.Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: https://medicine.iupui.edu/clinpharm/ddis/table.aspx August 18, 2011.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.